Loading
A phase 2 trial of Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT01081951 by AstraZeneca, with 162 participants enrolled, started 2010-02-04 and due to reach its primary completion in 2011-10-10. Interventions recorded: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatin. Conditions listed: Ovarian Cancer. Results were posted on ClinicalTrials.gov in 2012; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
162 enrolled.
95% CI 9.7 to 15.0; Figures from the ClinicalTrials.gov results section (first posted 2012-12-10), not from a publication · 95% CI 9.1 to 9.7
SourceFigures from the ClinicalTrials.gov results section (first posted 2012-12-10), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Olaparib/Carboplatin AUC4/Paclitaxel | 81 | 12.2 months | 0.51 (0.34 to 0.77) | 0.0012 | link |
| Carboplatin AUC6/Paclitaxel | 81 | 9.6 months | ||||
| Overall Survival (OS) | Olaparib/Carboplatin AUC4/Paclitaxel | 81 | 54 participants (number of deaths) | 1.17 (0.79 to 1.73) | 0.4379 | link |
| Carboplatin AUC6/Paclitaxel | 81 | 47 participants (number of deaths) |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Platinum agents, Carboplatin, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares Platinum-sensitive ovarian cancer, Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/